Mirum Pharmaceuticals CEO Peetz sells $1.8M in stock

On November 4, 2026, Mirum Pharmaceuticals CEO Christopher Peetz sold 20,000 shares of the company's common stock, generating a total of $1,800,000. The shares were sold at a rate of $90 per share, following a Rule 10b5-1 trading plan he established on March 2, 2026. Since then, the stock price has risen to $96.97, signifying a 38% increase over the past year, though InvestingPro analysis suggests it is currently overvalued.

In contrast, Peetz simultaneously bought 20,000 shares of Mirum Pharmaceuticals through the exercise of fully vested employee stock options, acquiring them at a price of $2.936 per share, which amounted to a cost of $58,720. He currently owns a total of 206,637 shares of Mirum Pharmaceuticals common stock, including 187,500 shares indirectly held by The Peetz Family Trust and 38,487 employee stock options.

Despite the recent stock sales, the company reported strong third-quarter 2026 product sales of $185.7 million, exceeding estimates and showcasing a 40% year-over-year growth. However, Mirum Pharmaceuticals also reported an EPS of -$0.87, which was lower than the -$0.49 analyst estimate. Despite the earnings miss, investment firms such as H.C.

Wainwright, Raymond James, and Citizens have raised their price targets for the company, signaling confidence in its future performance.